Certara Gelecekteki Büyüme
Future kriter kontrolleri 3/6
Certara kazanç ve gelirin sırasıyla yıllık 78.8% ve 0.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 82.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 1.6% olacağı tahmin edilmektedir.
Anahtar bilgiler
78.8%
Kazanç büyüme oranı
82.60%
EPS büyüme oranı
| Healthcare Services kazanç büyümesi | 21.7% |
| Gelir büyüme oranı | 0.8% |
| Gelecekteki özkaynak getirisi | 1.57% |
| Analist kapsamı | Good |
| Son güncelleme | 13 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Seeking Alpha • Apr 26
Certara: An Interesting Situation To Keep Track Off
Summary Certara divested its regulatory and medical writing business for up to $135 million, shifting focus to core operations and AI-integrated drug modeling. Post-divestiture, Certara will have a net cash position and a simplified business but faces flattish growth and lingering AI disruption concerns. Valuation multiples have compressed to ~2.6x sales and ~8x EBITDA, with shares trading near all-time lows despite historical growth and a now-unleveraged balance sheet. I remain curious but cautious, given the lack of organic growth, 20x forward earnings multiple, and uncertain AI impact, despite improved financial flexibility. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Apr 25
CERT: FDA PBPK Acceptance And Biosimulation Wins Will Support Future Core Relevance
Analysts have revised Certara's fair value estimate, with the updated price target modestly lower as they incorporate reduced assumptions for revenue growth and profit margins, along with a substantially higher expected future P/E multiple. Analyst Commentary Recent Street research on Certara has turned more cautious, with multiple firms cutting price targets and several moving to more neutral ratings.Anlatı Güncellemesi • Apr 07
CERT: Biosimulation And FDA Modeling Wins Will Underpin Future Core Relevance
Narrative Update on Certara The analyst price target on Certara has shifted lower, with several firms moving their targets into the $8 to $10 range. This reflects concerns around a Q4 services miss, slower software bookings, updated 2026 guidance, and a perceived need for greater investment to support core growth.Anlatı Güncellemesi • Mar 23
CERT: Biosimulation Leadership And FDA Modeling Wins Will Support Future Relevance
Analysts trimmed their fair value estimate for Certara from $9.60 to $9.19 per share, citing lower price targets across the Street, more conservative assumptions for revenue growth and valuation multiples, and ongoing questions around execution after recent guidance and services softness. Analyst Commentary Street research around Certara has turned more cautious overall, with several firms reducing price targets and, in some cases, ratings.Anlatı Güncellemesi • Mar 09
CERT: Biosimulation Leadership And FDA Use Of Modeling Will Support Shares
The analyst price target for Certara has been reduced by $2.77 to $9.60 as analysts factor in softer Q4 services results, slower software bookings, a more cautious 2026 outlook, and increased uncertainty around the pace of core growth despite the company’s position in model informed drug development. Analyst Commentary Recent research has turned more cautious on Certara, with a series of target cuts and rating changes following Q4 results, updated 2026 guidance, and ongoing questions around core growth and execution.Anlatı Güncellemesi • Feb 23
CERT: Biosimulation Leadership And New CEO Appointment Will Support Shares
Analysts have trimmed their average price target for Certara by $1 to $12, reflecting slightly higher discount rate assumptions and modestly lower future P/E expectations, even as they continue to highlight the company as a leader in biosimulation with what they view as an improving demand backdrop. Analyst Commentary Recent Street research paints a mixed picture for Certara, with some analysts focusing on long term growth drivers in biosimulation and others flagging near term execution and valuation questions.Analiz Makalesi • Feb 12
Certara, Inc.'s (NASDAQ:CERT) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Certara, Inc. ( NASDAQ:CERT ) shares have had a horrible month, losing 26% after a relatively good period beforehand...Anlatı Güncellemesi • Feb 08
CERT: Biosimulation Expansion And New CEO Hire Will Support Shares
Analysts have trimmed their average price target on Certara to about $12, down from roughly $13. This reflects a mix of caution around competition and regulatory pressure, as well as continued confidence in the company's position in biosimulation and its potential to expand further into early stage drug development.Anlatı Güncellemesi • Jan 25
CERT: Biosimulation Leadership And New CEO Transition Should Support Shares Recovery
Analysts have trimmed their price expectations for Certara, with the consensus target easing by about $1 to reflect slightly lower valuation multiples tied to competition, regulatory questions, softer services bookings, and leadership changes, while still highlighting the company's position in biosimulation and potential benefits from acquisitions such as Chemaxon. Analyst Commentary Recent research on Certara points to a mixed but generally constructive tone, with analysts balancing confidence in the core biosimulation franchise against execution risks in services, competition, and regulatory questions.Anlatı Güncellemesi • Jan 10
CERT: Biosimulation Expansion And New CEO Should Support Shares Rebound
Analysts have trimmed their average price target on Certara by about $0.17 to roughly $12.38. This reflects recent cuts to some individual targets alongside continued recognition of the company as a leader in biosimulation and expectations that prior stock weakness tied to bookings, biopharma budget timing, and leadership changes may have been overdone.Anlatı Güncellemesi • Dec 18
CERT: Shares Will Benefit From Biosimulation Expansion As Pharma Rebound Unfolds
Analysts have modestly trimmed their blended price target on Certara from $13.21 to $12.54 per share, reflecting slightly lower growth and valuation assumptions, even as they highlight the company’s leadership in biosimulation and long term opportunity in modernizing drug development. Analyst Commentary Street research remains mixed on Certara, with most analysts recognizing the company’s strategic positioning in biosimulation and drug development modernization, while diverging on the pace of execution and appropriate valuation.Analiz Makalesi • Dec 08
Does Certara (NASDAQ:CERT) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Anlatı Güncellemesi • Dec 04
CERT: Shares Will Benefit From Biosimulation Leadership As Pharma Rebound Emerges
The analyst price target for Certara has been modestly reduced from $13.50 to about $13.21, as analysts balance near term headwinds in services bookings with growing confidence in the company’s leadership in biosimulation and its longer term role in modernizing drug development. Analyst Commentary Recent research updates reflect a generally constructive but selective stance on Certara, with views splitting between enthusiasm for its strategic position in biosimulation and caution around execution risk and near term bookings softness.Anlatı Güncellemesi • Nov 20
CERT: Shares Will Benefit From Pharma Rebound And Drug Development Modernization
Analysts have reduced Certara's fair value price target from $14.75 to $13.50, citing revised growth expectations, softer profit margins, and a need for clearer evidence of traction in core initiatives. Analyst Commentary Recent analyst research highlights a range of perspectives on Certara, with differing views on both its near-term prospects and longer-term potential within the drug development sector.Anlatı Güncellemesi • Nov 06
CERT: Shares Poised To Gain From Pharma And Biotech Sector Rebound Ahead
Analyst Price Target Update for Certara Analysts have maintained their price target for Certara at $14.75 per share, citing the company's strong positioning in the anticipated pharma and biotech rebound as well as an attractive current valuation relative to its long-term prospects. Analyst Commentary Analyst perspectives on Certara highlight a mix of optimism and caution as the company positions itself within a strengthening pharmaceutical and biotechnology sector.Anlatı Güncellemesi • Oct 23
Analysts Maintain Certara Price Target as Pharma Sector Recovery and New Developments Drive Outlook
Analysts have maintained their price target for Certara at $14.75, citing the company’s positioning at the center of a recovering pharma and biotech sector as a key reason for their continued positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts highlight Certara's central position in the anticipated rebound of the pharma and biotech sectors.Anlatı Güncellemesi • Oct 08
EMA Approval And AI Integration Will Drive Biosimulation Despite Risks
Certara's analyst price target has increased from $14.11 to $14.75. This change reflects analysts' optimism about the company's strategic position in the pharma sector and its potential to benefit from growing R&D investment trends.Analiz Makalesi • Oct 07
Subdued Growth No Barrier To Certara, Inc. (NASDAQ:CERT) With Shares Advancing 28%
Certara, Inc. ( NASDAQ:CERT ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...Analiz Makalesi • Sep 04
A Look At The Fair Value Of Certara, Inc. (NASDAQ:CERT)
Key Insights Certara's estimated fair value is US$11.21 based on 2 Stage Free Cash Flow to Equity Certara's US$10.50...Analiz Makalesi • Aug 14
Shareholders Will Be Pleased With The Quality of Certara's (NASDAQ:CERT) Earnings
NasdaqGS:CERT 1 Year Share Price vs Fair Value Explore Certara's Fair Values from the Community and select yours When...Anlatı Güncellemesi • Aug 08
EMA Approval And AI Integration Will Drive Biosimulation Despite Risks
The slight downward revision in Certara’s price target reflects a modest reduction in its future P/E ratio, while revenue growth expectations remain essentially unchanged, resulting in a new consensus price target of $14.11. What's in the News Certara reiterated full-year 2025 revenue guidance of $415 million to $425 million.Analiz Makalesi • Aug 08
Some Investors May Be Worried About Certara's (NASDAQ:CERT) Returns On Capital
NasdaqGS:CERT 1 Year Share Price vs Fair Value Explore Certara's Fair Values from the Community and select yours If we...Analiz Makalesi • Jul 18
Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)
Certara, Inc.'s ( NASDAQ:CERT ) price-to-sales (or "P/S") ratio of 4.3x may not look like an appealing investment...Analiz Makalesi • Jun 27
Is Certara (NASDAQ:CERT) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Yeni Anlatı • Jun 08
FDA Phaseout And AI Integration Will Expand Biosimulation Demand
Regulatory shifts and long-term outsourcing trends are boosting demand for Certara's biosimulation and data-driven modeling solutions, supporting recurring revenue growth and market expansion.Analiz Makalesi • May 07
Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...Analiz Makalesi • Apr 15
Certara, Inc.'s (NASDAQ:CERT) 32% Price Boost Is Out Of Tune With Revenues
Certara, Inc. ( NASDAQ:CERT ) shareholders have had their patience rewarded with a 32% share price jump in the last...Seeking Alpha • Apr 11
Buy Certara After The FDA Announcement
Summary The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials. Certara's 2025 revenue forecast is $415-$425 million, with an EBITDA margin of 30-32%, making CERT stock an attractive speculative buy. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 29
Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching
While Certara, Inc. ( NASDAQ:CERT ) might not have the largest market cap around , it saw significant share price...Analiz Makalesi • Feb 27
Here's Why Certara (NASDAQ:CERT) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jan 11
Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up
When close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...Analiz Makalesi • Dec 19
Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?
Key Insights Certara's estimated fair value is US$8.10 based on 2 Stage Free Cash Flow to Equity Certara is estimated...Analiz Makalesi • Nov 15
Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Analiz Makalesi • Oct 24
Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued?
Certara, Inc. ( NASDAQ:CERT ), is not the largest company out there, but it saw significant share price movement during...Analiz Makalesi • Sep 20
Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 435 | 12 | N/A | 93 | 4 |
| 12/31/2027 | 405 | -2 | 82 | 97 | 12 |
| 12/31/2026 | 398 | -17 | 62 | 87 | 12 |
| 3/31/2026 | 420 | -15 | 63 | 91 | N/A |
| 12/31/2025 | 419 | -2 | 70 | 96 | N/A |
| 9/30/2025 | 416 | 11 | 92 | 117 | N/A |
| 6/30/2025 | 406 | 8 | 77 | 102 | N/A |
| 3/31/2025 | 394 | -3 | 70 | 94 | N/A |
| 12/31/2024 | 385 | -12 | 59 | 80 | N/A |
| 9/30/2024 | 373 | -31 | 35 | 54 | N/A |
| 6/30/2024 | 364 | -79 | 51 | 69 | N/A |
| 3/31/2024 | 361 | -61 | 61 | 77 | N/A |
| 12/31/2023 | 354 | -55 | 67 | 83 | N/A |
| 9/30/2023 | 353 | -34 | 81 | 95 | N/A |
| 6/30/2023 | 352 | 19 | 74 | 87 | N/A |
| 3/31/2023 | 344 | 14 | 80 | 93 | N/A |
| 12/31/2022 | 336 | 15 | 80 | 93 | N/A |
| 9/30/2022 | 324 | -4 | 66 | 78 | N/A |
| 6/30/2022 | 314 | -10 | 63 | 74 | N/A |
| 3/31/2022 | 301 | -12 | 55 | 65 | N/A |
| 12/31/2021 | 286 | -13 | 51 | 60 | N/A |
| 9/30/2021 | 275 | -58 | 44 | 52 | N/A |
| 6/30/2021 | 262 | -55 | 40 | 48 | N/A |
| 3/31/2021 | 253 | -49 | 34 | 41 | N/A |
| 12/31/2020 | 244 | -49 | 37 | 45 | N/A |
| 9/30/2020 | 233 | -1 | 45 | 54 | N/A |
| 6/30/2020 | 226 | 1 | 31 | 41 | N/A |
| 3/31/2020 | 215 | -5 | 30 | 40 | N/A |
| 12/31/2019 | 209 | -9 | N/A | 38 | N/A |
| 12/31/2018 | 164 | -33 | N/A | 12 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: CERT önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: CERT önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: CERT önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: CERT şirketinin gelirinin (yıllık 0.8% ) US pazarından (yıllık 11.6% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: CERT şirketinin gelirinin (yıllık 0.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: CERT 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 1.6 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/20 10:30 |
| Gün Sonu Hisse Fiyatı | 2026/05/20 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Certara, Inc. 18 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Joseph Vruwink | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |